Sichuan Goldstone Asia Pharmaceutical Inc. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 484.265 million compared to CNY 609.722 million a year ago. Operating loss was CNY 91.769 million compared to operating Income of CNY 87.442 million a year ago. Net loss was CNY 95.152 million compared to net income of CNY 67.436 million a year ago. Basic loss per share from continuing operations was CNY 0.24 compared to basic earnings per share from continuing operations of CNY 0.17 a year ago.